Controversies about occult hepatitis B virus infection

World Journal of Gastroenterology

Volumn 15, Issue 39, 2009, Pages 4986-4987

  Ozaslan, Ersan ^a   Purnak, Tugrul ^a  

^a ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Definition; Management; Occult hepatitis B; Reactivation

Indexed keywords

NUCLEOSIDE ANALOG; RITUXIMAB; VIRUS DNA; ANTIVIRUS AGENT; HEPATITIS B ANTIGEN;

ARTICLE; CHRONIC HEPATITIS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CIRRHOSIS; NONHUMAN; SIDE EFFECT; STEM CELL TRANSPLANTATION; VIRUS HEPATITIS; VIRUS REACTIVATION; BLOOD; GENETICS; IMMUNOLOGY; NOTE; PRACTICE GUIDELINE; VIRUS LOAD; VIRUS REPLICATION;

ANTIVIRAL AGENTS; DNA, VIRAL; HEPATITIS B ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; PRACTICE GUIDELINES AS TOPIC; VIRAL LOAD; VIRUS REPLICATION;

EID: 73949115283     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.15.4986     Document Type: Article

References (14)

1. Shi YH, Shi CH. Molecular characteristics and stages of chronic hepatitis B virus infection. World J Gastroenterol 2009; 15: 3099-3105
2. Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, Craxì A, Donato F, Ferrari C, Gaeta GB, Gerlich WH, Levrero M, Locarnini S, Michalak T, Mondelli MU, Pawlotsky JM, Pollicino T, Prati D, Puoti M, Samuel D, Shouval D, Smedile A, Squadrito G, Trépo C, Villa E, Will H, Zanetti AR, Zoulim F. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 2008; 49: 652-657
3. Torbenson M, Thomas DL. Occult hepatitis B. Lancet Infect Dis 2002; 2: 479-486
4. Chemin I, Trépo C. Clinical impact of occult HBV infections. J Clin Virol 2005; 34 Suppl 1: S15-S21
5. Berasain C, Betés M, Panizo A, Ruiz J, Herrero JI, Civeira MP, Prieto J. Pathological and virological findings in patients with persistent hypertransaminasaemia of unknown aetiology. Gut 2000; 47: 429-435
6. Hui CK, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, Leung N, Luk JM, Lie AK, Kwong YL, Liang R, Lau GK. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006; 131: 59-68
7. Knöll A, Boehm S, Hahn J, Holler E, Jilg W. Long-term surveillance of haematopoietic stem cell recipients with resolved hepatitis B: high risk of viral reactivation even in a recipient with a vaccinated donor. J Viral Hepat 2007; 14: 478-483
8. Umemura T, Kiyosawa K. Fatal HBV reactivation in a subject with anti-HBs and anti-HBc. Intern Med 2006; 45: 747-748
9. Sarrecchia C, Cappelli A, Aiello P. HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb. J Infect Chemother 2005; 11: 189-191
10. Law JK, Ho JK, Hoskins PJ, Erb SR, Steinbrecher UP, Yoshida EM. Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations. Leuk Lymphoma 2005; 46: 1085-1089
11. Umemura T, Tanaka E, Kiyosawa K, Kumada H. Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan. Clin Infect Dis 2008; 47: e52-e56
12. Marzano A, Angelucci E, Andreone P, Brunetto M, Bruno R, Burra P, Caraceni P, Daniele B, Di Marco V, Fabrizi F, Fagiuoli S, Grossi P, Lampertico P, Meliconi R, Mangia A, Puoti M, Raimondo G, Smedile A. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis 2007; 39: 397-408
13. Barclay S, Pol S, Mutimer D, Benhamou Y, Mills PR, Hayes PC, Cameron S, Carman W. The management of chronic hepatitis B in the immunocompromised patient: recommendations from a single topic meeting. J Clin Virol 2008; 41: 243-254
14. European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-242